STAT3 is a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells as well as to the pathogenesis of many inflammatory and fibrotic diseases.
Inhibition of STAT3 in cancer has been shown to inhibit tumorigenesis as well as reverse immunosuppression within the tumor microenvironment. TTI-101 is currently being studied in the following clinical trials:
Phase 2: TTI-101 as Monotherapy and in Combination for Hepatocellular Carcinoma - Recruiting
Phase 2: TTI-101 in Combination for Metastatic HR+ HER2- Breast Cancer - Recruiting
Phase 1: TTI-101 in Advanced Cancers - Completed Recruiting
Chronic Inflammation and Fibrosis
The pro-proliferative and pro-survival activity of STAT3 is a central mediator in chronic inflammation and fibrosis. TTI-101 is currently being studied in the following clinical trials:
Phase 2: TTI-101 in Idiopathic Pulmonary Fibrosis – Recruiting
Expanded Access to Investigational, Unapproved Medicines
We believe that our fastest path to fulfill our commitment to patients is to focus on working with the FDA to complete the required clinical studies needed to demonstrate safety and effectiveness of our investigational therapy TTI-101 for multiple cancer indications. This focus on completing our clinical trials will help us expeditiously achieve the best outcome for the greatest number of patients suffering from cancer.
Currently, Tvardi Therapeutics does not have an Expanded Access Program for any advanced cancers. We encourage patients to discuss their treatment options, including clinical trials, with their medical team.